Castle Biosciences Inc to Acquire Myriad myPath® Laboratory Transcript
Good morning, and welcome to Castle Biosciences myPath Melanoma conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session regarding the transaction.
I would like to turn the call over to Frank Stokes, CFO. Please go ahead.
Thank you, operator. Good morning, everyone. Welcome to the call. Joining me today is Castle's Founder, President and Chief Executive Officer, Derek Maetzold.
Information recorded on this call speaks only as of today, April 27, 2021. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately 3 weeks.
Before we begin, I'd like to remind you that some of the information discussed today may contain projections or other forward-looking statements regarding
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |